Alimera Sciences - Stock Price History | ALIM

Historical daily share price chart and data for Alimera Sciences since 2021 adjusted for splits. The latest closing stock price for Alimera Sciences as of October 15, 2021 is 4.40.
  • The all-time high Alimera Sciences stock closing price was 182.76 on November 24, 2010.
  • The Alimera Sciences 52-week high stock price is 12.25, which is 178.4% above the current share price.
  • The Alimera Sciences 52-week low stock price is 3.82, which is 13.2% below the current share price.
  • The average Alimera Sciences stock price for the last 52 weeks is 7.35.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Alimera Sciences Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 5.4120 8.1600 8.1600 3.1200 4.2200 -44.33%
2019 11.0201 12.7436 17.8411 3.2984 7.5800 -29.59%
2018 15.3653 19.7901 20.3748 10.7661 10.7661 -46.01%
2017 20.3933 16.7916 25.3253 16.7916 19.9400 23.15%
2016 24.6991 37.0315 39.7301 15.8921 16.1919 -55.37%
2015 61.5799 87.1064 87.8561 30.2849 36.2819 -56.32%
2014 87.9682 69.1154 118.2909 65.9670 83.0585 17.87%
2013 49.6127 24.4378 80.9595 24.4378 70.4648 199.36%
2012 37.6850 19.7901 65.5172 18.6057 23.5382 25.60%
2011 107.7149 160.7196 161.4693 17.5412 18.7406 -87.96%
2010 141.4225 164.9175 182.7586 99.2504 155.6222 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.030B $0.051B
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00